Literature DB >> 25058482

Reproducibility of spectral-domain optical coherence tomography retinal thickness measurements and conversion to equivalent time-domain metrics in diabetic macular edema.

Susan B Bressler1, Allison R Edwards2, Kakarla V Chalam3, Neil M Bressler1, Adam R Glassman2, Glenn J Jaffe4, Michele Melia2, David D Saggau5, Oren Z Plous6.   

Abstract

IMPORTANCE: Understanding measurement variability and relationships between measurements obtained on different optical coherence tomography (OCT) machines is critical for clinical trials and clinical settings.
OBJECTIVE: To evaluate the reproducibility of retinal thickness measurements from OCT images obtained by time-domain (TD) (Stratus; Carl Zeiss Meditec) and spectral-domain (SD) (Cirrus; Carl Zeiss Meditec, and Spectralis; Heidelberg Engineering) instruments and formulate equations to convert retinal thickness measurements from SD-OCT to equivalent values on TD-OCT. DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional observational study was conducted in private and institutional practices. Persons with diabetes mellitus who had at least 1 eye with central-involved diabetic macular edema, defined as Stratus central subfield thickness (CST) of 250 μm or greater, participated. An additional normative cohort (individuals with diabetes but without diabetic macular edema) was enrolled. Each study eye underwent 2 replicate Stratus scans followed by 2 replicate Cirrus or Spectralis scans (real-time image registration used) centered on the fovea. MAIN OUTCOMES AND MEASURES: Optical coherence tomography CST and macular volume.
RESULTS: The Bland-Altman coefficient of repeatability for relative change in CST (the degree of change that could be expected from measurement variability) was lower with Spectralis (7%) compared with Cirrus (14%) and Stratus (12% and 15% within Cirrus/Stratus and Spectralis/Stratus groups, respectively). For each cohort, the initial Stratus CST was within 10% of the replicate Stratus measurement nearly all of the time; the conversion equations predicted a Stratus CST within 10% of the observed thickness 86% and 89% of the time for Cirrus/Stratus and Spectralis/Stratus groups, respectively, which is similar to the agreement on Stratus test-retest. The Bland-Altman limits of agreement for relative change in CST between machines (the degree of change that could be expected from measurement variability [combining within and between instrument variability]) were 21% for Cirrus and 19% for Spectralis when comparing predicted vs actual Stratus measurement. CONCLUSIONS AND RELEVANCE: Reproducibility appears to be better with Spectralis than with Cirrus and Stratus. Conversion equations to transform Cirrus or Spectralis measurements to Stratus-equivalent values, within 10% of the observed Stratus thickness values, appear feasible. Central subfield thickness changes beyond 10% when using the same machine or 20% when switching machines, after conversion to Stratus equivalents, are likely due to a change in retinal thickness rather than measurement error.

Entities:  

Mesh:

Year:  2014        PMID: 25058482      PMCID: PMC4366946          DOI: 10.1001/jamaophthalmol.2014.1698

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  13 in total

1.  Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.

Authors:  Michael J Elman; Lloyd Paul Aiello; Roy W Beck; Neil M Bressler; Susan B Bressler; Allison R Edwards; Frederick L Ferris; Scott M Friedman; Adam R Glassman; Kellee M Miller; Ingrid U Scott; Cynthia R Stockdale; Jennifer K Sun
Journal:  Ophthalmology       Date:  2010-04-28       Impact factor: 12.079

2.  Comparison of macular thickness measurements between time domain and spectral domain optical coherence tomography.

Authors:  Christopher Kai-shun Leung; Carol Yim-lui Cheung; Robert N Weinreb; Gary Lee; Dusheng Lin; Chi Pui Pang; Dennis S C Lam
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04-30       Impact factor: 4.799

3.  Evaluation of time domain and spectral domain optical coherence tomography in the measurement of diabetic macular edema.

Authors:  Farzin Forooghian; Catherine Cukras; Catherine B Meyerle; Emily Y Chew; Wai T Wong
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-05-30       Impact factor: 4.799

4.  Conversion of Stratus optical coherence tomography (OCT) retinal thickness to Cirrus OCT values in age-related macular degeneration.

Authors:  Ilse Krebs; Stefan Hagen; Eva Smretschnig; Irene Womastek; Werner Brannath; Susanne Binder
Journal:  Br J Ophthalmol       Date:  2011-02-24       Impact factor: 4.638

5.  Transitioning from stratus OCT to cirrus OCT: a comparison and a proposed equation to convert central subfield macular thickness measurements in healthy subjects.

Authors:  Gelareh Abedi; Payal Patal; Gheorghe Doros; Manju L Subramanian
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-07-01       Impact factor: 3.117

6.  Repeatability of retinal thickness measurements between spectral-domain and time-domain optical coherence tomography images in macular disease.

Authors:  Amitha Domalpally; Sapna Gangaputra; Qian Peng; Ronald P Danis
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2010-03-30

7.  Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation.

Authors:  Joseph Googe; Alexander J Brucker; Neil M Bressler; Haijing Qin; Lloyd P Aiello; Andrew Antoszyk; Roy W Beck; Susan B Bressler; Frederick L Ferris; Adam R Glassman; Dennis Marcus; Cynthia R Stockdale
Journal:  Retina       Date:  2011-06       Impact factor: 4.256

8.  Reproducibility of diabetic macular edema estimates from SD-OCT is affected by the choice of image analysis algorithm.

Authors:  Elliott H Sohn; John J Chen; Kyungmoo Lee; Meindert Niemeijer; Milan Sonka; Michael D Abràmoff
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-06-19       Impact factor: 4.799

9.  Retinal thickness in people with diabetes and minimal or no diabetic retinopathy: Heidelberg Spectralis optical coherence tomography.

Authors:  Kakarla V Chalam; Susan B Bressler; Allison R Edwards; Brian B Berger; Neil M Bressler; Adam R Glassman; Sandeep Grover; Shailesh K Gupta; Jared S Nielsen
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-12-13       Impact factor: 4.799

10.  Repeatability of Spectralis OCT measurements of macular thickness and volume in diabetic macular edema.

Authors:  Oliver Comyn; Ling Zhi Heng; Felicia Ikeji; Kanom Bibi; Philip G Hykin; James W Bainbridge; Praveen J Patel
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-11-21       Impact factor: 4.799

View more
  36 in total

Review 1.  Recent advancements in diabetic retinopathy treatment from the Diabetic Retinopathy Clinical Research Network.

Authors:  Carl W Baker; Yi Jiang; Thomas Stone
Journal:  Curr Opin Ophthalmol       Date:  2016-05       Impact factor: 3.761

2.  Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Adam R Glassman; Carl W Baker; Wesley T Beaulieu; Neil M Bressler; Omar S Punjabi; Cynthia R Stockdale; Charles C Wykoff; Lee M Jampol; Jennifer K Sun
Journal:  JAMA Ophthalmol       Date:  2020-04-01       Impact factor: 7.389

3.  RANIBIZUMAB PLUS PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA IN EYES WITH VITRECTOMY BEFORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.

Authors:  Susan B Bressler; Michele Melia; Adam R Glassman; Talat Almukhtar; Lee M Jampol; Michel Shami; Brian B Berger; Neil M Bressler
Journal:  Retina       Date:  2015-12       Impact factor: 4.256

Review 4.  Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option.

Authors:  M Ashraf; A Souka; R Adelman; S H Forster
Journal:  Eye (Lond)       Date:  2016-08-26       Impact factor: 3.775

5.  Prevalence and Severity of Artifacts in Optical Coherence Tomographic Angiograms.

Authors:  Ian C Holmen; Sri Meghana Konda; Jeong W Pak; Kyle W McDaniel; Barbara Blodi; Kimberly E Stepien; Amitha Domalpally
Journal:  JAMA Ophthalmol       Date:  2020-02-01       Impact factor: 7.389

6.  Structural changes of macular inner retinal layers in early normal-tension and high-tension glaucoma by spectral-domain optical coherence tomography.

Authors:  Florian S M Edlinger; Laura M Schrems-Hoesl; Christian Y Mardin; Robert Laemmer; Friedrich E Kruse; Wolfgang A Schrems
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-03-09       Impact factor: 3.117

7.  A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema.

Authors:  Henry E Wiley; Darby J S Thompson; Clare Bailey; Emily Y Chew; Catherine A Cukras; Glenn J Jaffe; Richard W J Lee; Erin K Loken; Catherine B Meyerle; Wai Wong; Frederick L Ferris
Journal:  Ophthalmology       Date:  2016-02-10       Impact factor: 12.079

8.  Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results.

Authors:  Michael J Elman; Allison Ayala; Neil M Bressler; David Browning; Christina J Flaxel; Adam R Glassman; Lee M Jampol; Thomas W Stone
Journal:  Ophthalmology       Date:  2014-10-28       Impact factor: 12.079

9.  Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.

Authors:  John A Wells; Adam R Glassman; Allison R Ayala; Lee M Jampol; Lloyd Paul Aiello; Andrew N Antoszyk; Bambi Arnold-Bush; Carl W Baker; Neil M Bressler; David J Browning; Michael J Elman; Frederick L Ferris; Scott M Friedman; Michele Melia; Dante J Pieramici; Jennifer K Sun; Roy W Beck
Journal:  N Engl J Med       Date:  2015-02-18       Impact factor: 91.245

10.  Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.

Authors:  John A Wells; Adam R Glassman; Lee M Jampol; Lloyd Paul Aiello; Andrew N Antoszyk; Carl W Baker; Neil M Bressler; David J Browning; Crystal G Connor; Michael J Elman; Frederick L Ferris; Scott M Friedman; Michele Melia; Dante J Pieramici; Jennifer K Sun; Roy W Beck
Journal:  JAMA Ophthalmol       Date:  2016-02       Impact factor: 7.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.